Trulicity (Dulaglutide) Future Formulations and Pipeline: What Comes Next

How Dulaglutide Works: The Mechanism Behind Trulicity

Dulaglutide is a long-acting GLP-1 receptor agonist engineered by fusing a modified GLP-1 analog to an IgG4 Fc fragment, extending its half-life to approximately 5 days and enabling once-weekly dosing. It mimics endogenous GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through central hypothalamic signaling.

Glucose-Dependent Insulin Secretion

The GLP-1 receptor sits on pancreatic beta cells. When dulaglutide binds it, intracellular cAMP rises, priming insulin granule exocytosis only when ambient glucose is elevated. This glucose-dependent mechanism is why GLP-1 agonists carry a lower hypoglycemia risk than sulfonylureas. A 2014 phase 3 analysis across the AWARD trial program confirmed severe hypoglycemia rates below 1% with dulaglutide monotherapy 1.

Beyond Blood Sugar: Cardiovascular and Weight Effects

The REWIND trial (N=9,901) randomized patients with type 2 diabetes to dulaglutide 1.5 mg weekly or placebo for a median 5.4 years. The primary endpoint, 3-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke), was reduced by 12% (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) 2. REWIND stands out because 69% of enrolled patients had no prior cardiovascular event, making it the first GLP-1 RA trial to show MACE reduction in a primary-prevention-predominant cohort.

Appetite Suppression and Weight

Dulaglutide produces modest weight loss (1.5 to 3 kg over 26 to 52 weeks in AWARD trials), less than semaglutide 2.4 mg (14.9% in STEP-1) or tirzepatide (up to 22.5% in SURMOUNT-1). This weight-loss gap is a central reason Lilly pivoted its pipeline toward newer molecules.

Why Lilly Moved Beyond Dulaglutide

Trulicity peaked at $7.4 billion in annual revenue in 2022. But the drug's competitive position eroded once semaglutide (Ozempic/Wegovy) demonstrated superior A1c reduction and weight loss in head-to-head SUSTAIN and STEP trials.

The SURPASS Trials Changed the Calculus

Lilly's own tirzepatide outperformed dulaglutide directly. In SURPASS-1 through SURPASS-5, tirzepatide 15 mg reduced A1c by up to 2.58% versus approximately 1.5% for dulaglutide 1.5 mg. Weight loss with tirzepatide reached 11.0 to 12.4 kg in diabetes populations 3. Once a company's own newer molecule outperforms its established product, R&D resources shift.

Patent Cliff and Biosimilar Exposure

Dulaglutide's core U.S. Composition-of-matter patent expired in 2025. The FDA's 351(k) pathway allows biosimilar GLP-1 RA applications, and several manufacturers have initiated development. Lilly has little incentive to invest in new dulaglutide formulations when biosimilar competition will compress margins while next-generation assets promise higher efficacy.

Eli Lilly's Active GLP-1 Pipeline: The Successors

Lilly's incretin pipeline now centers on three molecules that surpass dulaglutide in efficacy, route flexibility, or both. Each represents a distinct strategic bet.

Tirzepatide: The Dual Agonist Already in Market

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) activates both GIP and GLP-1 receptors. In SURMOUNT-1 (N=2,539), participants without diabetes lost 20.9% of body weight at the 15 mg dose over 72 weeks, versus 3.1% on placebo 4. The dual-agonist mechanism amplifies insulin sensitivity through GIP-receptor-mediated effects on adipose tissue that GLP-1 monoagonists like dulaglutide do not produce.

Tirzepatide is the direct clinical successor for most patients considering dulaglutide. It is available in the same once-weekly injectable format, with 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses. Its cardiovascular outcomes trial (SURPASS-CVOT) has completed enrollment and results are expected to define whether tirzepatide earns a MACE-reduction indication comparable to what REWIND established for dulaglutide.

Orforglipron: The Oral Small-Molecule GLP-1 Agonist

Orforglipron is a non-peptide, small-molecule oral GLP-1 receptor agonist. Unlike oral semaglutide (Rybelsus), which requires an absorption enhancer (SNAC) and strict fasting instructions, orforglipron is a conventional small molecule absorbed without special conditions.

In a phase 2 trial (N=272), orforglipron 45 mg daily reduced body weight by 14.7% at 36 weeks in adults with obesity, compared with 2.3% for placebo 5. A1c reductions in participants with type 2 diabetes reached 2.1% at the 45 mg dose. Phase 3 trials (ACHIEVE program) are ongoing with results expected in 2025 to 2026.

If approved, orforglipron eliminates the injection barrier entirely. That matters. Surveys consistently show 20 to 30% of patients with type 2 diabetes delay injectable therapy due to needle aversion, according to data reviewed by the American Diabetes Association 6.

Retatrutide: The Triple Agonist

Retatrutide targets three receptors simultaneously: GIP, GLP-1, and glucagon. The glucagon component adds thermogenic energy expenditure on top of the appetite suppression and insulin sensitization provided by GIP/GLP-1 co-agonism.

Phase 2 data (N=338) showed weight reductions of 24.2% at 48 weeks with retatrutide 12 mg, the largest weight loss reported for any anti-obesity drug in a controlled trial at the time of publication 7. Phase 3 trials are underway. The glucagon-receptor component raises theoretical hepatic safety questions, but phase 2 liver fat reductions were dramatic: up to 86% relative reduction in hepatic steatosis, suggesting potential MASH/MASLD applications 8.

What About an Oral Dulaglutide Formulation?

No oral formulation of dulaglutide is in development. Dulaglutide is a large fusion protein (approximately 63 kDa) that cannot survive gastrointestinal degradation without radical reformulation. Novo Nordisk solved this for semaglutide (a much smaller peptide at 4.1 kDa) by co-formulating with the absorption enhancer SNAC, but oral bioavailability remains low at approximately 1% 9.

Why Reformulation Is Unlikely

For a protein of dulaglutide's size, oral delivery would require encapsulation technologies (e.g., ionic-liquid formulations, nanoparticle carriers, or device-based intestinal injectors like the SOMA capsule developed at MIT). These technologies remain pre-commercial for large biologics. Lilly has chosen the simpler path: develop a new small-molecule oral agonist (orforglipron) rather than attempt to reformulate an existing large biologic.

The Small-Molecule Advantage

Small-molecule GLP-1 agonists like orforglipron (Lilly) and danuglipron (Pfizer, though Pfizer shifted to a once-daily formulation after twice-daily dosing showed tolerability issues) represent the industry consensus. Oral small molecules offer conventional pharmacokinetics, standard manufacturing, and no cold-chain requirements. Dulaglutide's engineering as a fusion protein, once its greatest strength for enabling weekly dosing, now makes it a poor candidate for oral reformulation when purpose-built oral molecules exist.

Dulaglutide's Role in the Evolving Treatment Algorithm

The 2024 ADA Standards of Care recommend GLP-1 RAs with proven cardiovascular benefit as preferred second-line agents in type 2 diabetes after metformin, particularly for patients with established atherosclerotic cardiovascular disease or high risk 10. Dulaglutide, semaglutide, and liraglutide all hold this indication based on CVOT data.

Where Dulaglutide Still Fits

Dulaglutide retains clinical relevance in specific scenarios. Patients who tolerate Trulicity well and have stable A1c may not benefit from switching to a newer agent. The REWIND cardiovascular data remain strong. For patients who do not need aggressive weight loss (BMI in the 25 to 30 range with well-controlled diabetes), dulaglutide's moderate weight effect is sufficient.

Where It Falls Short

For patients who need significant weight reduction (BMI >35), dual or triple agonists offer substantially greater efficacy. The Endocrine Society's 2023 clinical practice guideline on pharmacological treatment of obesity recommends agents with the highest demonstrated weight-loss efficacy when BMI exceeds 30 kg/m² or 27 kg/m² with comorbidities 11. Tirzepatide and, eventually, retatrutide outperform dulaglutide on this metric by a wide margin.

Biosimilar Entry and Cost Implications

As biosimilar dulaglutide products enter the market, cost will likely decrease by 15 to 40%, based on patterns observed with biosimilar adalimumab and insulin glargine. According to an IQVIA analysis, biosimilar competition in GLP-1 RAs could improve access for the estimated 37.3 million Americans with diabetes tracked by the CDC 12. Lower-cost dulaglutide biosimilars may become a pragmatic first GLP-1 RA for cost-sensitive patients or health systems.

Other GLP-1 Pipeline Candidates Beyond Lilly

Lilly does not operate in isolation. The broader GLP-1 and incretin pipeline includes molecules from multiple manufacturers that will reshape the competitive field dulaglutide occupies.

Semaglutide Extensions (Novo Nordisk)

Novo Nordisk continues to expand semaglutide's indications. The SELECT trial (N=17,604) demonstrated a 20% reduction in MACE with semaglutide 2.4 mg in adults with overweight/obesity and established cardiovascular disease but without diabetes 13. This was the first CVOT to show cardiovascular benefit for a GLP-1 RA in a non-diabetic population. Semaglutide is also under investigation for MASH, heart failure with preserved ejection fraction (STEP-HFpEF showed significant improvement in symptoms and physical limitations), and chronic kidney disease.

CagriSema (Novo Nordisk)

CagriSema combines semaglutide with cagrilintide, a long-acting amylin analog. The amylin component adds additional appetite suppression through area postrema signaling. Phase 2 data showed up to 15.6% weight loss at 32 weeks. Phase 3 results are expected in 2025 to 2026.

Survodutide (Boehringer Ingelheim)

Survodutide is a dual glucagon/GLP-1 agonist (different receptor pairing than tirzepatide's GIP/GLP-1). Phase 2 data in adults with obesity showed up to 18.7% weight loss at 46 weeks 14. A phase 2 MASH trial showed histological resolution of steatohepatitis in 83% of patients at the highest dose. The glucagon component drives hepatic fat reduction more aggressively than GLP-1 alone.

Pemvidutide (Altimmune)

Pemvidutide, another GLP-1/glucagon dual agonist, showed 15.6% weight loss at 48 weeks in a phase 2 trial. Its differentiator is a pronounced effect on liver fat, positioning it as a potential MASH therapy.

What Current Trulicity Patients Should Know

Patients on dulaglutide do not need to switch immediately. The drug remains FDA-approved, widely available, and clinically effective. But planning ahead is prudent.

Discuss Transition Timing

If A1c goals are met and cardiovascular risk is managed, there is no clinical urgency to change. If weight loss is a treatment priority or A1c remains above target on dulaglutide 4.5 mg, a conversation about tirzepatide or semaglutide is warranted. The ADA notes that treatment intensification should not be delayed when glycemic targets are not met within 3 to 6 months 10.

Monitor Biosimilar Availability

Biosimilar dulaglutide could lower out-of-pocket costs. Patients with high copays on branded Trulicity should ask their prescriber and pharmacist about biosimilar options as they become available. Formulary changes by insurers may also shift preferred-agent status, making it important to review coverage annually.

Oral Options on the Horizon

For patients who dislike weekly injections, orforglipron's potential approval could offer a daily pill with comparable efficacy. Clinical decisions should wait for phase 3 data and FDA review, but patients can ask their clinician about trial eligibility through ClinicalTrials.gov.

Dulaglutide's composition-of-matter patent has expired, no new formulations are in development, and Eli Lilly's pipeline has moved decisively toward tirzepatide, orforglipron, and retatrutide. Clinicians prescribing Trulicity today should monitor SURPASS-CVOT results and orforglipron phase 3 readouts to inform transition planning for their patient panels.